Principles and practical strategies for immunotherapy in genitourinary malignancies

IPCE : 1 + more
Start Date :  Jul 01, 2021End Date :  Jun 01, 2022

Duration :  60 Minutes

Organized by :   ReachMD

Specialties :   Immunotherapies, Women's Health Nurse, Oncology

Fees Fee :   Starting From Free

Conference Summary

Principles and practical strategies for immunotherapy in genitourinary malignancies is organized by ReachMD.

Release Date: 07/01/2021
Expiration Date: 06/01/2022

Target Audience:
This activity is aimed at oncologists, urologists, surgeons, pharmacists, medical assistants, oncology nurses and other health professionals involved in the treatment of genitourinary cancer.

Accreditation:
Declaration of recognition:

This activity was organized by and for the health team, and students will receive 1.0 credit from Interprofessional Continuing Education (interdisciplinary continuing education - IPCE) for learning and change.

Credit assignment for doctors:
AXIS Medical Education assigns a maximum of 1.0 AMA PRA Category 1 Credit(s)™ to this permanent material . Doctors should only request credit proportional to their participation in the activity.

Allocation of credits to medical assistants:
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to offer AAPA Category 1 CME credits for activities organized in accordance with AAPA CME criteria. This activity offers 1.0 AAPA category 1 CME credit. The approval is valid until 06/01/2022. Assistant physicians should only apply for credit proportional to their participation.

Credit assignment for pharmacists:
This application-based activity has been approved for 1.0 hour of continuing education contact at pharmacy JA4008106-0000-20-077-H01-P.

Credit allocation for nurses:
AXIS Medical Education gives this continuing education activity for nursing 1.0 hours of contact.

Description:
Advances in therapy with immunological checkpoint inhibitors are transforming the way doctors treat and manage metastatic UC and RCC. Considering the approval of immunological checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, as well as the emergence of more evidence, it can be challenging to understand how to better incorporate these therapies into current treatment strategies.

This activity will analyze the latest clinical advances, emerging data and recommendations for immunotherapy guidelines for the treatment of advanced renal cell carcinoma and urothelial carcinoma.

Learning Objectives:
At the conclusion of this activity, participants must have a better ability to:
• To evaluate the evidence supporting the use of immunological checkpoint inhibitors for the first-line treatment of advanced or metastatic urothelial carcinoma and renal cell carcinoma
• To analyze the role of first-line maintenance treatment with immunological checkpoint inhibitors in metastatic urothelial carcinoma
• Compare survival data for sequential immunotherapy and standard chemotherapy care for first-line treatment of metastatic urothelial carcinoma
• Develop evidence-based treatment sequencing strategies with immune checkpoint inhibitors and subsequent, first-line treatment of advanced or metastatic urothelial carcinoma and renal cell carcinoma

Credit Info

  • IPCE : 1
  • CME : 1
  • Contact Hours : 1
  • Credit : 1
  • Hours : 1
Contact Us

Toll free Number

1(800) 826-2059

Email

support@eMedEvents.com

Chat Assistant

Live Chat
Recommended